• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MG-ADL 在重症肌无力全身无力中的敏感性。

Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.

机构信息

Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.

Department of Biostatistics, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Eur J Neurol. 2019 Jun;26(6):947-950. doi: 10.1111/ene.13867. Epub 2018 Dec 17.

DOI:10.1111/ene.13867
PMID:30417962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6590478/
Abstract

BACKGROUND AND PURPOSE

Myasthenia gravis activities of daily living (MG-ADL) is a commonly used questionnaire in MG trials. To investigate whether MG-ADL is equally sensitive to oculobulbar and generalized weakness, its correlation with the oculobulbar and generalized domain of the quantitative myasthenia gravis (QMG) score was analyzed (QMGob and QMGgen, respectively). To test whether the sensitivity of MG-ADL for generalized weakness could be improved, the additional value of ACTIVLIM on top of MG-ADL in the prediction QMGgen in was investigated.

METHODS

MG-ADL, QMG and ACTIVLIM, an ADL questionnaire focusing on generalized weakness, were analyzed in a prospective cohort of 112 MG patients. A generalized linear model was used to calculate the correlation of MG-ADL with QMGob and QMGgen and to assess the additional value of ACTIVLIM on top of MG-ADL for its correlation with QMGgen.

RESULTS

MG-ADL had a higher correlation with QMGob than with QMGgen (B = 0.68, P < 0.001, and B = 0.38, P < 0.001, respectively). A similar trend was found for changes in the scores (B = 0.68, P = 0.132, and B = 0.39, P = 0.492, respectively). ACTIVLIM had a significant additional value on top of MG-ADL in the prediction of QMGgen, both cross-sectionally (B = -0.61, P < 0.001) and for changes within individual patients (B = -0.93, P = 0.041).

CONCLUSION

MG-ADL has a lower sensitivity for generalized weakness than for oculobulbar weakness. Adding questions on generalized weakness would improve the sensitivity of the MG-ADL for generalized weakness.

摘要

背景与目的

重症肌无力日常生活活动(MG-ADL)是重症肌无力试验中常用的问卷。为了研究 MG-ADL 是否同样敏感于眼肌和全身无力,分析了其与定量重症肌无力(QMG)评分的眼肌和全身域(QMGob 和 QMGgen)的相关性(分别为 QMGob 和 QMGgen)。为了测试 MG-ADL 对全身无力的敏感性是否可以提高,研究了在 MG-ADL 基础上增加 ACTIVLIM 对预测 QMGgen 的额外价值。

方法

在 112 例重症肌无力患者的前瞻性队列中分析了 MG-ADL、QMG 和 ACTIVLIM,这是一种侧重于全身无力的 ADL 问卷。使用广义线性模型计算 MG-ADL 与 QMGob 和 QMGgen 的相关性,并评估 ACTIVLIM 在 MG-ADL 基础上对其与 QMGgen 的相关性的额外价值。

结果

MG-ADL 与 QMGob 的相关性高于与 QMGgen 的相关性(B=0.68,P<0.001,B=0.38,P<0.001)。分数的变化也呈现出类似的趋势(B=0.68,P=0.132,B=0.39,P=0.492)。ACTIVLIM 在预测 QMGgen 方面对 MG-ADL 具有显著的额外价值,无论是在横截面(B=-0.61,P<0.001)还是在个体患者的变化(B=-0.93,P=0.041)。

结论

MG-ADL 对全身无力的敏感性低于对眼肌无力的敏感性。增加关于全身无力的问题将提高 MG-ADL 对全身无力的敏感性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a70/6590478/c0323df77786/ENE-26-947-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a70/6590478/c0323df77786/ENE-26-947-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a70/6590478/c0323df77786/ENE-26-947-g001.jpg

相似文献

1
Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.MG-ADL 在重症肌无力全身无力中的敏感性。
Eur J Neurol. 2019 Jun;26(6):947-950. doi: 10.1111/ene.13867. Epub 2018 Dec 17.
2
Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.重症肌无力障碍指数:对全身肌无力变化的敏感性。
J Neuromuscul Dis. 2020;7(3):297-300. doi: 10.3233/JND-200484.
3
Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.吸烟与眼肌型重症肌无力患者的日常生活活动
J Neuroophthalmol. 2016 Mar;36(1):37-40. doi: 10.1097/WNO.0000000000000306.
4
Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.在 MGTX 研究中定量重症肌无力和重症肌无力日常生活活动量表的相关性。
Muscle Nerve. 2020 Aug;62(2):261-266. doi: 10.1002/mus.26910. Epub 2020 Jun 4.
5
Activity limitations in myasthenia gravis and relation to clinical variables.
Muscle Nerve. 2017 Jul;56(1):64-70. doi: 10.1002/mus.25463. Epub 2016 Dec 2.
6
Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.在3期REGAIN研究中,抗乙酰胆碱受体抗体阳性难治性全身型重症肌无力患者的重症肌无力日常生活活动能力(MG-ADL)与重症肌无力定量评估(QMG)之间的相关性。
Muscle Nerve. 2018 Aug;58(2):E21-E22. doi: 10.1002/mus.26152. Epub 2018 May 18.
7
QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.QMG与MG-ADL的相关性:依库珠单抗治疗重症肌无力的研究。
Muscle Nerve. 2017 Aug;56(2):328-330. doi: 10.1002/mus.25529. Epub 2017 Feb 25.
8
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.依氟鸟氨酸对全身型重症肌无力患者肌肉亚群的影响:III 期关键性 ADAPT 研究的事后分析。
Eur J Neurol. 2024 Jan;31(1):e16098. doi: 10.1111/ene.16098. Epub 2023 Oct 16.
9
Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.依库珠单抗治疗难治性全身性重症肌无力的长期疗效:应答者分析。
Ann Clin Transl Neurol. 2021 Jul;8(7):1398-1407. doi: 10.1002/acn3.51376. Epub 2021 May 27.
10
Translation and validation of the arabic version of the myasthenia gravis activities of daily living scale.重症肌无力日常生活活动量表阿拉伯文版的翻译和验证。
Muscle Nerve. 2019 May;59(5):583-586. doi: 10.1002/mus.26435. Epub 2019 Feb 12.

引用本文的文献

1
Short-term outcome prediction for myasthenia gravis: an explainable machine learning model.重症肌无力的短期预后预测:一种可解释的机器学习模型。
Ther Adv Neurol Disord. 2023 Feb 24;16:17562864231154976. doi: 10.1177/17562864231154976. eCollection 2023.
2
Outcomes and characteristics of myasthenia gravis: A 10-year retrospective cross-sectional study at King Fahad Medical City.重症肌无力的结局和特征:法赫德国王医疗城的一项 10 年回顾性横断面研究。
Neurosciences (Riyadh). 2022 Oct;27(4):237-243. doi: 10.17712/nsj.2022.4.20220038.
3
Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis.

本文引用的文献

1
Distinct representation of muscle weakness in QMG and MG-ADL.肌无力在定量重症肌无力评分(QMG)和重症肌无力日常生活活动量表(MG-ADL)中的不同表现。
Lancet Neurol. 2018 Mar;17(3):204-205. doi: 10.1016/S1474-4422(18)30037-1.
2
Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.重症肌无力损伤指数:反应性、有意义的变化及相对效率。
Neurology. 2017 Dec 5;89(23):2357-2364. doi: 10.1212/WNL.0000000000004676. Epub 2017 Nov 3.
3
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
重症肌无力中的不同单克隆抗体:一项贝叶斯网络荟萃分析。
Front Pharmacol. 2022 Jan 18;12:790834. doi: 10.3389/fphar.2021.790834. eCollection 2021.
4
In-depth peripheral CD4 T profile correlates with myasthenic crisis.深入的外周 CD4 T 谱与肌无力危象相关。
Ann Clin Transl Neurol. 2021 Apr;8(4):749-762. doi: 10.1002/acn3.51312. Epub 2021 Feb 22.
5
Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial.皮下注射免疫球蛋白在重症肌无力中的药效学特性:一项开放标签试验的亚组分析
Front Neurol. 2020 Aug 25;11:921. doi: 10.3389/fneur.2020.00921. eCollection 2020.
6
Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.重症肌无力障碍指数:对全身肌无力变化的敏感性。
J Neuromuscul Dis. 2020;7(3):297-300. doi: 10.3233/JND-200484.
依库珠单抗治疗乙酰胆碱受体抗体阳性的难治性全身性重症肌无力(REGAIN)的安全性和有效性:一项 3 期、随机、双盲、安慰剂对照、多中心研究。
Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20.
4
Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.皮下注射免疫球蛋白治疗重症肌无力加重期:一项前瞻性、开放标签试验。
Neurology. 2017 Sep 12;89(11):1135-1141. doi: 10.1212/WNL.0000000000004365. Epub 2017 Aug 16.
5
Activity limitations in myasthenia gravis and relation to clinical variables.
Muscle Nerve. 2017 Jul;56(1):64-70. doi: 10.1002/mus.25463. Epub 2016 Dec 2.
6
Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls.重症肌无力:不常见的表现和诊断陷阱。
J Neuromuscul Dis. 2016 Aug 30;3(3):413-418. doi: 10.3233/JND-160148.
7
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.甲氨蝶呤治疗全身型重症肌无力患者的一项随机对照试验。
Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15.
8
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.自身免疫性重症肌无力:新出现的临床和生物学异质性
Lancet Neurol. 2009 May;8(5):475-90. doi: 10.1016/S1474-4422(09)70063-8.
9
Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionnaire.神经肌肉疾病患者的活动受限情况:ACTIVLIM问卷的反应性研究
Neuromuscul Disord. 2009 Feb;19(2):99-103. doi: 10.1016/j.nmd.2008.11.004. Epub 2009 Jan 23.
10
ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders.ACTIVLIM:一种基于拉施模型构建的用于评估神经肌肉疾病儿童和成人活动受限情况的测量工具。
Neuromuscul Disord. 2007 Jun;17(6):459-69. doi: 10.1016/j.nmd.2007.02.013. Epub 2007 Apr 11.